Search
for
Sort by
Research 451–480 of 1000+
- 細胞配置と力学的刺激の複合効果がもたらす毛髪および皮膚附属器官の完全生体外再生
- Evolution of hard proteins in the sauropsid integument in relation to the cornification of skin derivatives in amniotes
- Polymeric nanocapsular baicalin: Chemometric optimization, physicochemical characterization and mechanistic anticancer approaches on breast cancer cell lines
- Unveiling the Potential of Single‐Cell Encapsulation in Biomedical Applications: Current Advances and Future Perspectives
- Bubble-Based Drug Delivery Systems: Next-Generation Diagnosis to Therapy
- Fast Motions in 5 Alpha Reductase and Its Impact on Enzyme Kinetics
- N‑K GM SERIES: COMPLETE HAIR MEDICINES COLLECTION — From L‑Series Longevity to Dedicated Hair Restoration: BALDNESS-GM1, HAIR-REMOVE-GM1, and the Complete Hair Health Protocol
- N‑K GM SERIES: COMPLETE HAIR MEDICINES COLLECTION — From L‑Series Longevity to Dedicated Hair Restoration: BALDNESS-GM1, HAIR-REMOVE-GM1, and the Complete Hair Health Protocol
- Novel delivery strategy: finasteride-loaded solid lipid nanoparticles for improved androgenetic alopecia therapy
- Report on the 11th National Congress AICPE (Associazione Italiana di Chirurgia Plastica Estetica) Held in Rimini, Italy, 12–14 April 2024
- Chitosan and its amphiphilic derivative nanoparticles loaded with Minoxidil for induction of hair growth: In vitro and in vivo evaluation
- Notch Signaling Regulates Late-Stage Epidermal Differentiation and Maintains Postnatal Hair Cycle Homeostasis
- Liposomes and Ethosomes: Comparative Potential in Enhancing Skin Permeability for Therapeutic and Cosmetic Applications
- Direct-to-Consumer Teledermatology Growth: A Review and Outlook for the Future
- Extracellular Vesicles for Androgenetic Alopecia: Current Evidence, Mechanisms, and Clinical Prospects
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- Clinical Applications of Punch-Based Techniques in Dermatologic Surgery
- 3a-Phenylhexahydropentalene-1,6-dione
- Multi-modal skin atlas identifies a multicellular immune-stromal community associated with disrupted cornification and specific T cell expansion in atopic dermatitis
- Animals in Dermatology
- Mapping Human Skin: One Sequenced Cell at a Time
- 715 Hunting the hair cycle clock (HCC): Evidence that mitochondrially localized MPZL3 is a key HCC element in murine and human hair follicles
- 880 Divergent trends in acne vulgaris interest and research a decade of lost face value in the United States
- 1333 Spheroids cell cultures as a promising study model for hair follice regeneration
- Smart Responsive Microneedles for Controlled Drug Delivery
- The Multifaceted Functions of TRPV4 and Calcium Oscillations in Tissue Repair
- Past, Present, and Future of Plant-Derived Extracellular Vesicles in Biomedical Applications
- Topical Delivery of Tofacitinib in Dermatology: The Promise of a Novel Therapeutic Class Using Biodegradable Dendritic Polyglycerol Sulfates
- Evidence for Novel Functions of the Keratin Tail Emerging from a Mutation Causing Ichthyosis Hystrix